Your browser doesn't support javascript.
loading
Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting.
Tamiya, Akihiro; Tamiya, Motohiro; Inagaki, Yuji; Taniguchi, Yoshihiko; Nakao, Keiko; Matsuda, Yoshinobu; Kawamura, Takahisa; Kunimasa, Kei; Inoue, Takako; Nishino, Kazumi; Okishio, Kyoichi.
Afiliación
  • Tamiya A; Department of Internal Medicine, Kinki-Chuo Chest Medical Center, Sakai, Japan.
  • Tamiya M; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan; moto19781205@yahoo.co.jp.
  • Inagaki Y; Department of Internal Medicine, Kinki-Chuo Chest Medical Center, Sakai, Japan.
  • Taniguchi Y; Department of Internal Medicine, Kinki-Chuo Chest Medical Center, Sakai, Japan.
  • Nakao K; Department of Internal Medicine, Kinki-Chuo Chest Medical Center, Sakai, Japan.
  • Matsuda Y; Department of Internal Medicine, Kinki-Chuo Chest Medical Center, Sakai, Japan.
  • Kawamura T; Department of Internal Medicine, Kinki-Chuo Chest Medical Center, Sakai, Japan.
  • Kunimasa K; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Inoue T; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Nishino K; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Okishio K; Department of Clinical Research Center, Kinki-Chuo Chest Medical Center, Sakai, Japan.
Anticancer Res ; 43(3): 1325-1330, 2023 Mar.
Article en En | MEDLINE | ID: mdl-36854522
BACKGROUND/AIM: Regimens with bevacizumab (Bev) have high response rates. We previously showed the efficacy of Bev plus carboplatin (CBDCA)/nab-paclitaxel (nab-PTX) in the treatment of non-squamous (non-SQ) non-small lung cell cancer (NSCLC) with malignant pleural effusion in a phase II trial. However, few studies have reported the efficacy and safety of this regimen. Therefore, we conducted a retrospective analysis of the efficacy and safety of Bev plus CBDCA/nab-PTX for patients with NSCLC. PATIENTS AND METHODS: We included patients with non-SQ NSCLC that underwent any number of treatment lines. Patients received a maximum of six cycles of Bev plus CBDCA/nab-PTX every three to four weeks followed by Bev plus nab-PTX every three to four weeks without disease progression or severe toxicities. The administration dose was left to the discretion of the attending physician. RESULTS: We enrolled 48 patients treated with Bev plus CBDCA/nab-PTX between June 2015 and August 2021. The best response rate was 56.3% and the disease control rate was 79.2%. Twenty-three patients received maintenance therapy. Median progression-free and overall survival times were 6.8 and 10.4 months, respectively. Common adverse events included hematological toxicities, including ≥grade 3 neutropenia and neurosensory toxicity. One patient experienced severe bleeding events (grade 3 gastrointestinal bleeding) and another experienced grade 5 toxicity (infection). CONCLUSION: The combination of Bev plus CBDCA/nab-PTX showed good efficacy with acceptable toxicities in non-SQ NSCLC patients, despite the inclusion of patients with late treatment lines and poor performance status.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares / Neutropenia Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Anticancer Res Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares / Neutropenia Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Anticancer Res Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Grecia